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Abstract
Background: The purpose of clinical trials of acupuncture is to help clinicians and patients make decisions about
treatment. Yet this is not straightforward: some trials report acupuncture to be superior to sham (placebo)
acupuncture while others show evidence that acupuncture is superior to usual care but not sham, and still others
conclude that acupuncture is no better than usual care. Meta-analyses of these trials tend to come to somewhat
indeterminate conclusions. This appears to be because, until recently, acupuncture research was dominated by
small trials of questionable quality. The Acupuncture Trialists’ Collaboration, a group of trialists, statisticians and
other researchers, was established to synthesize patient-level data from several recently published large, high-
quality trials.
Methods: There are three distinct phases to the Acupuncture Trialists Collaboration: a systematic review to identify
eligible studies; collation and harmonization of raw data; statistical analysis. To be eligible, trials must have
unambiguous allocation concealment. Eligible pain conditions are osteoarthritis; chronic headache (tension or
migraine headache); shoulder pain; and non-specific back or neck pain. Once received, patient-level data will
undergo quality checks and the results of prior publications will be replicated. The primary analysis will be to
determine the effect size of acupuncture. Each trial will be evaluated by analysis of covariance with the principal
endpoint as the dependent variable and, as covariates, the baseline score for the principal endpoint and the
variables used to stratify randomization. The effect size for acupuncture from each trial - that is, the coefficient and
standard error from the analysis of covariance - will then be entered into a meta-analysis. We will compute effect
sizes separately for comparisons of acupuncture with sham acupuncture, and acupuncture with no acupuncture
control for each pain condition. Other analyses will investigate the impact of different sham techniques, styles of
acupuncture or frequency and duration of treatment sessions.
Discussion: Individual patient data meta-analysis of high-quality trials will provide the most reliable basis for
treatment decisions about acupuncture. Above all, however, we hope that our approach can serve as a model for
future studies in acupuncture and other complementary therapies.
Background
Introduction
The term “acupuncture” is used to describe a heteroge-
neous set of healthcare practices, with a spectrum
of styles from “traditional” acupuncture through to
“Western” acupuncture. Common to these styles of
acupuncture is the insertion and stimulation of needles
at specific points on the body to facilitate recovery of
health.
Chronic pain is the most common presenting condi-
tion for acupuncturists in the Western world [1,2]. Pain
has also be the focus of most clinical research on acu-
puncture. In June 2010, MEDLINE listed slightly over
1100 English-language randomized trials for acupunc-
ture and approximately half of these concerned pain.
The clear and obvious purpose of such trials is to
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inform clinical practice. However, using acupuncture
trials to aid clinical decisions is not straightforward. To
use a simple example, imagine that a patient with
chronic low back pain consulted with a physician to
determine whether acupuncture might be an appropriate
treatment. The physician is unsure of the evidence and
so searches MEDLINE using the terms ‘acupuncture’
and ‘back pain’ with ‘randomized controlled trial’ publi-
cation type as a limit. This retrieves 74 different papers,
some of which suggest that acupuncture is superior to
both sham (placebo) acupuncture and no acupuncture
control [3]; others that report acupuncture to be super-
ior to no acupuncture but not to sham acupuncture [4]
and yet others failing to find differences between acu-
puncture and no acupuncture [5]. This illustrates the
need for studies that synthesize existing research.
There have been a large number of systematic reviews
on acupuncture for pain. For example, the 2nd issue of
the Cochrane Library for 2007 listed 12 Cochrane Colla-
boration reviews of acupuncture for pain, with over 50
additional non-Cochrane systematic reviews published
on this topic. As an example of an acupuncture sys-
tematic review, consider Ezzo et al.’s paper on acupunc-
ture for the treatment of chronic pain, published in
2000 [6]. This included 51 randomized trials of acu-
puncture for a variety of conditions, including back
pain, headache, osteoarthritis and dysmenorrhea. The
study can be seen as typical of acupuncture systematic
reviews for three reasons. First, the sample size of the
included studies was low: there were a total of 2423
patients in the 51 analyzed trials, with a median sample
size per group of 18. Second, the methodological quality
of the studies was questionable: 68% of the studies in
the review were defined as poor quality and only 3 of
the 51 studies received a maximum quality score. Third,
and as a consequence of the first two points, the conclu-
sions drawn by the reviewers are very tentative: “there is
limited evidence that acupuncture is more effective than
no treatment for chronic pain; and inconclusive evi-
dence that acupuncture is more effective than placebo”.
The landscape of clinical research in acupuncture
has recently been dramatically altered by the comple-
tion of several large, high quality trials. The first of
these to be published was a trial of acupuncture for
chronic headache disorders: the trial randomized 401
patients for acupuncture or usual care control [7] and,
at the time, was the largest randomized trial for acu-
puncture for pain conducted in the West; however, it
was quickly superseded by Berman et al.’s trial of acu-
puncture for osteoarthritis of the knee (n = 570) [8].
The German ART (Acupuncture Randomized Trials)
studies published in 2005 and early 2006 [4,9-11]
included close to 300 patients each in four separate
trials on osteoarthritis, chronic low back pain, migraine
and chronic tension headache. But even these trials are
dwarfed by the GERAC (GERman ACupuncture) trials
which accrued close to 1000 patients each on trials on
osteoarthritis [12], chronic low back pain [13] and
migraine [14] and 400 on chronic tension headache
[15]. The ARC (Acupuncture in Routine Care) trials
have even larger sample sizes: 3000 patients or more
on each three separate trials of back pain [16], neck
pain [17] and chronic headache [18], and 700 patients
on a trial of arthritis [19].
We suggest that the optimal method to synthesize
existing acupuncture trials is to conduct individual
patient data meta-analysis, including only the highest
quality trials. The Acupuncture Trialists’ Collaboration
was established to obtain raw data from investigators
and combine these into a single data set [20]. This data
set will be analyzed to address questions concerning
both the management of chronic pain conditions and
research design for acupuncture.
Objectives
Our overarching objective is:
1. To establish an individual patient level data-
base of raw data from high quality trials of acu-
puncture for chronic pain conditions. We will
analyze this database to address several key hypoth-
eses in acupuncture research.
Our primary analytic objectives are:
2. To determine whether real acupuncture is
superior to sham acupuncture for the treatment
of chronic pain conditions and, if so, to deter-
mine the effect size. Here ‘real acupuncture’ is
defined as the experimental intervention which the
investigators believe may have activity against pain.
‘Sham acupuncture’ is defined as any intervention
that is designed to prevent the patient from knowing
whether or not he or she received real acupuncture
but which is thought to have minimal activity
against pain.
3. To determine whether real acupuncture is
superior to no acupuncture control for the treat-
ment of chronic pain conditions and, if so, to
determine the effect size. ‘No acupuncture control’
is defined to include care, such as medication ‘as
needed’, that is also received by the acupuncture
group. No acupuncture controls are sometimes
described as ‘waiting list’ controls, ‘usual’ or ‘stan-
dard care’ controls or controls receiving ‘no addi-
tional treatment’. ‘Attention control’, where patients
receive general education and advice, are also
included in this category.
Vickers et al. Trials 2010, 11:90
http://www.trialsjournal.com/content/11/1/90
Page 2 of 13
For objectives 2 and 3, analyses will be conducted
separately for each pain condition (musculoskeletal,
osteoarthritis, headache) and then within pain condi-
tion (neck pain, shoulder pain, back pain; chronic
tension headache, migraine). Our secondary objec-
tives are:
1. To determine the effect size of acupuncture for
pain, function, health related quality of life and
medication use. These analyses will be conducted
separately for the different pain conditions and com-
parators, and at different follow-up times.
2. To determine which aspects of acupuncture
treatment or sham control affect outcome. These
analyses include questions such as whether effects
vary by the indication or the style of acupuncture,
or whether different practitioners have different
outcomes.
Methods/Design
The study is exempt from IRB oversight because it
involves analysis of de-identified data that has already
been collected for a separate purpose.
Phase I: Systematic review to identify eligible papers
Trial eligibility criteria
Methodology It has been demonstrated that uncon-
cealed allocation is the most important source of bias in
randomized trials [21,22]. We will therefore include only
those randomized trials of acupuncture for chronic pain
conditions where allocation concealment is determined
unambiguously to be adequate. In cases where this is
not clear from the published paper, we will contact
authors for further information concerning the exact
logistics of the randomization process.
The Acupuncture Trialists’ Collaboration will only
include trials with adequate allocation concealment. We
consider allocation to be adequately concealed if both of
the following two conditions hold:
1. Researchers were unable to predict the group to
which a patient would be randomized until the
patient was unambiguously registered on study.
2. Researchers were unable to change a patient’s
allocation after a patient was randomized.
Examples for adequate concealment of allocation are
given in table 1. Allocation concealment will be consid-
ered inadequate if participants or investigators enrolling
participants could possibly foresee or modify assign-
ments and thus introduce selection bias. Table 1
provides some examples of inadequate allocation
concealment.
In the case of envelope randomization, investigators
must establish clear procedures to ensure conditions 1
and 2 above. For example, there should be procedures
to prevent investigators resealing and reusing an envel-
ope after it was opened (e.g. envelopes are held by an
independent party); reading the contents (e.g. use of
cardboard or silver foil) or selecting multiple envelopes
(e.g. sequential numbering).
Patients Eligible pain conditions are osteoarthritis;
chronic or recurrent headaches such as tension or
migraine headache; specific and non-specific shoulder
pain; and non-specific back or neck pain. Trials of back
or neck pain associated with specific pathologies (e.g.
osteoporotic fracture) will be excluded. Trials of
shoulder pain associated with specific pathologies (e.g.
rotator cuff tendonitis, frozen shoulder, or bursitis) will
be included. Our rationale is that our main analyses will
be conducted separately by indication, and for indica-
tions other than those listed, we do not believe that we
will identify more than 1 or 2 eligible trials. For osteoar-
thritis and headache pain we will not require a specific
pain duration, as both are chronic in nature. Back, neck
and shoulder pain are episodic conditions and we will
use the criterion used in many trials that the current
episode must be of at least four weeks duration. In a
normal systematic review, summary data are analyzed
and so a trial is included only if all patients meet a cri-
terion. In an individual patient data meta-analysis, such
as this, we have the possibility of including a trial, but
excluding certain patients on that trial from analysis.
a) If a trialist can provide data on duration of symp-
toms, the trial is eligible. Only patients with a dura-
tion of 4 weeks or more are included in the analysis.
b) If a trialist does not provide data on duration of
symptoms, duration of 4 weeks or more must be an
eligibility criterion.
Interventions Trials where acupuncture points or trig-
ger points are stimulated by acupuncture needles. Trials
will be classed as ineligible if patients in the acupunc-
ture group, but not the control group, were protocolled
to receive medication (conventional or otherwise), sur-
gery or physical therapy.
Controls At least one group in the trial must receive
sham acupuncture or no acupuncture control.
Sham acupuncture is defined as any intervention
that is designed to prevent the patient from knowing
whether or not he or she received real acupuncture but
which is thought to have minimal activity against pain.
This includes superficial needle insertion; needle inser-
tion at non-acupuncture points or at points not indi-
cated for the condition under study; ‘placebo’ needles,
such as the Streitberger needle [23], which appear to
penetrate the skin but which do not do so; techniques,
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such as tapping on a guide-tube, designed to feel like
needle penetration; and non-needle methods such as
detuned lasers or deactivated transcutaneous electric
nerve stimulation devices. It is worth noting that we do
not consider these controls to be equivalent a priori;
possible differences between sham procedures will be
analyzed as one of our objectives.
No acupuncture control is defined as any of the fol-
lowing apply: 1) Care received in the control group is
also available to the acupuncture group. Examples
include a trial with waiting list control, one in which
patients receive usual clinical care with or without
acupuncture and a study where the effects of a course
of physiotherapy plus acupuncture are compared to
physiotherapy alone. This category may also include
studies where care in the acupuncture and control
groups is not identical, but does not differ in any
medically substantive manner. 2) The intervention in
the control group involves general advice, education
and support. This type of control is sometimes
described as ‘attention control’. 3) The control group,
but not the acupuncture group, received recommenda-
tions for guideline care, although no specific treat-
ment plan was mandated and no treatment was
provided by the trial. As is the case for sham acu-
puncture, we do not expect that these different types
of no acupuncture control will have equivalent effects,
but we will include different types of control in our
analyses and investigate differences between them.
Control groups will be excluded if, in addition to
sham acupuncture or treatments also available in the
true acupuncture group, controls received a specific
program of treatment such as medication, massage or
physical therapy.
Outcomes There is no restriction on eligibility due to
the type of endpoint. However, on the grounds that we
are interested in the effects of acupuncture on medium
and long-term pain, the primary endpoint must be mea-
sured more than four weeks after the initial acupuncture
treatment.
Trial size There will be no restrictions on the size of
the trial. However, for expediency, we will only invite as
collaborators trialists associated with trials of 100 or
more patients. Trialists of eligible studies with fewer
than 100 patients will be invited to submit raw data to
the collaboration but not to join the collaboration as a
member.
Language There are no language exclusions. All papers
in languages other than English will be translated into
English and the English text made available to all
collaborators.
Search strategy for identification of studies
We will search MEDLINE, CENTRAL (the Cochrane
Collaboration Database) and the citation lists of sys-
tematic reviews. The search strategy used will be as for
the prior reviews of headache [24], back pain [25] and
osteoarthritis [26] (each of which was co-authored by
one or more members of the Acupuncture Trialists Col-
laboration) with the addition of the following terms:
neck, shoulder, cervical, musculoskeletal.
Searching established databases for trials conducted in
China or published in the Chinese language is likely to
have very poor precision as very few of these studies are
of sufficient quality to merit inclusion in the Acupunc-
ture Trialists’ Collaboration [27-30]. Accordingly, trials
identified by the standard searches (e.g. of Medline) that
were conducted in China will not be considered further.
Chinese trials will be identified by a separate process:
Table 1 Examples of adequate and inadequate allocation concealment
Adequate allocation concealment Inadequate allocation concealment
Centralized randomization procedures in which the persons including a
patient contact the randomization center or a person otherwise not
involved in the trial who registers the patient as included in the trial and
only then provides the allocation information for this patient
An open random allocation schedule, that is, where all future allocations
can be read by an investigator
Any computerized system that ensures, by password protection or other
computer security procedures, conditions 1 and 2 described in the text
Envelopes, if clear details of the procedures used to avoid allocation
becoming unconcealed are inadequate, or unclear
Use of consecutively numbered, opaque sealed envelopes containing
the allocation information kept by a person otherwise not involved in
the study with envelopes opened only after registration of an included
patient
Assignment envelopes were used without appropriate safeguards (for
example if envelopes were unsealed or non-opaque or not sequentially
numbered)
Alternation, rotation, day of the week
Date of birth, or medical record number
Blocked randomization with block size known to the person including the
patient
An unspecified method, for example, if the report states only that
“patients were randomized” without giving details of the exact
procedures used, and no further information is obtained from the
authors.
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Jianping Liu of the Chinese Cochrane Center will use
that institution’s resources to identify trials of acupunc-
ture for chronic pain that involved full allocation
concealment.
Inclusion of studies
All retrieved references will be scanned by one of two
investigators to remove any clearly inappropriate titles.
Hard copies of all remaining papers will then be obtained
and read by both investigators to remove any for which
there is no possibility of eligibility. Inclusion criteria for
the remaining papers will be applied by two reviewers
separately (no reviewer may assess a trial on which he or
she is listed as a co-author). Disagreements about study
inclusion will be resolved by consensus. Authors of trials
will be contacted, if necessary, to clarify details such as
allocation concealment, if this is not clear. However,
authors will not be contacted if a trial has already been
included in a prior published systematic review conducted
by one of the collaborators: methodological details will be
taken from the published review. All retrieved trials
excluded from the review will be given reasons for exclu-
sion as follows: not a randomized trial; allocation unclear
or inadequate; not acupuncture; inappropriate control; not
pain; only short-term measurement of pain; not an
osteoarthritis, headache, back, neck or shoulder pain trial.
Quality assessment
Methodological quality The most important quality
criteria for a randomized trial concern the quality of
randomization, blinding, and exclusions and drop-outs
[21,22]. The quality of randomization is an inclusion cri-
terion for this study: only trials with full allocation con-
cealment will be analyzed. Exclusions and drop-outs will
be dealt with by multiple imputation in the statistical
analysis. Hence our quality assessment will focus on
blinding. For all studies involving sham acupuncture,
assessment of blinding will follow prior Cochrane
reviews in grading as A, B or C.
A: Low likelihood of bias: EITHER the adequacy of
blinding was checked by direct questioning of
patients, for example, with a credibility question-
naire, and no important differences were found
between groups OR a blinding method (e.g. the
Streitberger sham device) was used that had pre-
viously been validated as able to maintain blinding.
C: High likelihood of bias: Clear reasons to believe
that blinding was broken, for example, differential
responses to a credibility questionnaire or obviously
non-credible sham technique
B: Intermediate likelihood of bias: A trial that does
not meet the criteria for either a grade of A or C.
Note that the results of credibility questionnaires
given several weeks after treatment starts are of
questionable value as they are confounded by treat-
ment effects: a patient who experienced a rapid
improvement in symptoms after treatment would be
more likely to believe that he received real acupunc-
ture than a patient who did not benefit. Hence such
questionnaires will not be given prominence in the
assessment of blinding. Quality assessment will be con-
ducted by two reviewers separately with disagreements
resolved by consensus.
Adequacy of acupuncture treatment In addition to
assessing the quality of the trials, we will assess the
quality of the acupuncture delivered. The method was
developed by Hugh MacPherson, a member of the Acu-
puncture Trialists’ Collaboration, and the originator of
the STRICTA guidelines [31]. The criteria to assess the
adequacy of the acupuncture delivered are:
1.) Fidelity to an adequate protocol OR representa-
tive of good practice in the context of what is pro-
vided by the same practitioners within their region
2.) Number of sessions
3.) Acupuncturist experience
A panel of expert acupuncturists will be convened.
Each panel member will first provide a global assess-
ment for each of the above criteria with three possible
ratings: adequate, inadequate and not sufficiently well
reported. These ratings will be entered into a data
extraction sheet available for review by other panel
members. The scores of each rater for each of the three
above items will be sent to all panel members. Panel
members will then make a judgment about the overall
rating of the trial in the same categories of: adequate,
inadequate, or not sufficiently well reported to make a
judgment. Panel members are recused from assessing
any trial on which they are a co-author. Further docu-
mentation of the acupuncture techniques used is
described under “Data abstraction”.
Phase II: Collection, checking and harmonization of data
Development of the database
Individual patient data will be sought for all included
trials and entered into a single database. Data will be
obtained for all randomized patients, regardless of
whether they received treatment or provided post-ran-
domization data. Trial level data will then be added to
individual patient records. For example, a data set for a
trial might have an indicator variable for acupuncture vs
control. This will be replaced by several variables indi-
cating the type of acupuncture and type of control as
described in the trial report. Where raw data are not
available for a trial, we will conduct sensitivity analyses
to determine whether inclusion of the trial might alter
our results.
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Initial data manipulation
The raw data set will be saved in its original format,
then converted to a Stata format (Stata is the statistical
software used for analysis) and saved again. Three blank
statistical programs will then be saved out: one to
undertake preliminary checks on the data, one to
rename and label the variables and one to replicate sta-
tistics reported in the trial publication. All files will be
saved using a standard notation: “raw data [descriptor]”,
“initial import [descriptor]”, “initial set up [descriptor]”,
“initial data checks [descriptor]” and “replication
[descriptor]” where “[descriptor]” is a unique label for
each data set (e.g. “Linde 2005 migraine”).
Annotation checks
Statistical code will be written for the “initial set up”
program. Each variable in the raw data set will be
renamed to a standard notation (e.g. “age_at_randomiza-
tion” becomes “age”) and given a standard label (a label
is a text description of the variable, such as “combined
headache score at 60 days”, that is stored by the statisti-
cal software). Variables unique to a particular data set,
for example, a WOMAC score in an arthritis trial, will
then be identified and labeled. Any variables that cannot
be identified, or are ambiguous, will be documented,
and appropriate clarification sought from the original
investigator.
Checking for erroneous or missing data
Statistical code will be written for the “initial data checks”
program. First, the number of missing observations for
each variable will be calculated and checked against data
available in the original publication. Any inconsistencies,
or variables for which information on rates of missing
data are not available in the trial publication, will be
brought to the attention of the original investigator for
clarification. Second, “range” checks will be conducted
on all variables to determine whether all values are rea-
sonable. As a trivial example, a VAS of 123, or an age of
567 immediately suggest an error. Thirdly, we will check
categorical variables by tabulation. For instance, if 200
patients were categorized as having stage I disease, 220
categorized as having stage II disease and 1 as having
stage IIa disease, the investigator would be queried as to
the accuracy of the IIa categorization.
Replication
The third program “replication [descriptor]” will then be
written. This will attempt to replicate every number
reported on the trial publication. Replications will
include baseline characteristics such as age, sex and
duration of disease within each group; outcome data
such as pain scores within each group at each follow-up
time; and comparisons, such as the difference in pain
scores between groups at the post-treatment follow-up.
In each case, we will use the statistical methods reported
by the authors and derive the statistics given in the
publication. For example, if a mean and standard devia-
tion for baseline pain score is given in the trial publica-
tion, we will similarly calculate mean and standard
deviation; if the difference between groups is calculated
by linear regression with baseline score and duration of
disease as covariates, we will use exactly this method to
see if we obtain the same difference between groups,
95% C.I. and p value. Any discrepancies between our
results and those reported in the published paper will be
brought to the attention of the investigators for clarifica-
tion. We feel that any data set that has gone through
these checks - independent labeling of every variable;
assessment of prima facie errors; replication of all
reported statistics - can be considered valid for inclusion
in an independent patient data meta-analysis.
Harmonization
Variable names will be harmonized. To indicate time
point, variable names will start with “bl” for baseline
and “mj“ or “wj“ for month j and week j respectively.
Outcome will be categorized as per Additional file 1 and
a single tag chosen for each. For example, a visual ana-
log score at 3 months would be named “m3_vas”.
Phase III: Statistical methods
Overview
Individual patient data meta-analysis has long been
recognized as the ideal method of synthesizing research
data. In the words of Iain Chalmers, one of the founders
of the Cochrane Collaboration, using individual patient
data in a meta-analysis is the “yardstick” by which all
meta-analyses should be measured [32]. The advantages
of using individual patient data compared to traditional
reviews, which analyze published summary data, are as
follows [33,34]:
Standardization between different analytic approaches
Some trials of acupuncture have reported mean change
in pain, others have reported “response rates” of the
proportion of patients who experienced a threshold
reduction in pain (e.g. 33%). These results cannot be
combined without access to raw data, which allows con-
version from one type of analysis to another.
Application of statistical methods with greater power
In a typical meta-analysis, the investigator records mean
and standard deviations for acupuncture and control
groups separately. This does not allow the application of
techniques, such as analysis of covariance, that have
greater statistical power than unadjusted analysis
[35,36].
Association between patient-level characteristics and
outcome
Individual patient data analyses have far greater power
to investigate questions such as whether age or baseline
symptom severity influence outcome. As an example, if
there were four trials with 250 patients each, analysis of
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published data would attempt to correlate four values of
a predictor (e.g. mean age in each trial) with four values
of an outcome (e.g. difference between mean pain
scores). Analysis of individual patient data would be
able to create a model with 1000 data points.
Data quality
The process of combining data from different sources
requires careful data scrutiny by an independent investi-
gator. This provides an opportunity to identify and cor-
rect errors in the data set.
Updating trial results
This is an issue of particular importance for trials with
survival outcomes as data continue to accrue on a daily
basis after publication. This issue may be less pertinent
to the Acupuncture Trialists’ Collaboration, however, it
is possible that trialists have data from long-term fol-
low-up that has yet to be published.
On overview of the analyses to be conducted are given
in Figure 1.
Principal endpoint
For each trial, we will first identify the primary out-
come defined by the study authors in terms of both
the scale (e.g. WOMAC) and time point (e.g. 6
months after randomization). We will keep endpoints
on the continuous scale. For example, in some studies,
the primary endpoint was defined in terms of the pro-
portion of patients who had at least a 35% reduction
in the number of days with headache pain at 6 month
follow-up; in this case, the primary endpoint will be
number of days with pain at 6 months. If multiple cri-
teria are considered in the primary outcome, or if the
primary outcome is inherently categorical, we will use
a continuous measure of pain measured at the same
time point as the original primary endpoint. For
example, if a trial’s primary outcome is a response to
treatment defined as a given degree of improvement
of a pain scale or a function scale, we would select the
pain scale for inclusion in our primary analysis. If
there are multiple pain measurements we will select
one according to the Outcome Measure Preferences
(Additional file 1). For analyses that include trials with
different primary endpoints, we will create a standar-
dized primary endpoint by dividing by standard
deviation.
Figure 1 Overview of the analyses to be conducted.
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Primary analysis: analysis of the effect size of acupuncture
Each trial will be reanalyzed by analysis of covariance
with the standardized principal endpoint as the depen-
dent variable, and baseline principal endpoint and vari-
ables used to stratify randomization as covariates. This
approach has been shown to have the greatest statistical
power for trials in general with baseline and follow-up
measures [36] and also specifically applied to acupunc-
ture research [35]. For trials where randomization was
stratified by center or practitioner, this stratification will
be included in analysis only if there are 20 or fewer sites
and there are a mean of at least 20 patients per site,
with at least one patient in each arm at each site. In
trials where there is more than one acupuncture group,
for example, trials in which patients are randomized to
local points, distal points or sham points, results from
both real acupuncture groups will be combined (local
points and distal points in this case). The effect size for
acupuncture from each trial (i.e. the coefficient and
standard error) will then be entered into a meta-
analysis: the meta-analytic statistics are created by
weighting each coefficient by the reciprocal of the var-
iance, summing and dividing by the sum of the weights.
Meta-analysis will be accomplished using the metan
command in Stata (Stata Corp., College Station, TX).
Our primary analysis will be a fixed effects model. Our
rationale is that a fixed effects analysis constitutes a
valid test of the null hypothesis of no treatment effect.
Moreover, we take the view that the use of a fixed
effects model does not imply an assumption that all
trials are estimating the same effect, but that the robust-
ness of the fixed effects approach is likely to lead to a
more accurate estimate. Nonetheless, we will report the
results of the random effects analysis. We will also
report heterogeneity statistics [37].
We will compute effect sizes separately for compari-
sons of acupuncture with sham and no acupuncture
control. Comparisons between acupuncture and sham
will omit trials graded as C (’high likelihood of bias’) for
blinding. These analyses will be conducted separately for
each pain condition (specific shoulder conditions, mus-
culoskeletal, osteoarthritis, headache) and then within
pain condition (neck pain, back pain; chronic tension
headache, migraine).
Secondary analyses
We will repeat the analyses of effect size for the sec-
ondary endpoints of pain intensity, pain frequency,
functional impairment, combined measures of pain
and functional impairment, mental well-being (e.g.
SF-36 mental health), physical well-being (e.g. SF-36
physical health), overall quality of life (e.g. global
assessment), range of motion or stiffness, health
change, satisfaction with care and medication use. If
a trial reports more than one endpoint that can be
placed in a particular category, the outcomes mea-
sure preference list (Additional file 1) will be con-
sulted to select the most appropriate measure. On
occasion this may involve taking a mean score of two
endpoints, for example, if a trial reported both a day-
time and nighttime VAS score, we would calculate
the average for each patient and the combined score
would then be entered into analysis. Note that this
demonstrates a key advantage of individual patient
data meta-analysis: such a data manipulation would
not be possible with summary level data. As it likely
that different measurement scales will be used in the
different trials, we anticipate that we will use stan-
dardized mean differences as the meta-analytic
statistic.
Time will always be measured from randomization.
For our data, we will use endpoints of 1, 2, 3, 6 and 9
months and one year. For outcomes with these exact
time points (or the equivalent in another unit of time:
13 weeks = 3 months), no time point standardization
is required. Otherwise, the time point closest to the
selected scheme is adopted. For example, if there is
no measurement at 6 months but there is for 24
weeks, this timepoint will be selected and relabeled
appropriately.
Numerical rating scale (NRS) scores will be converted
to a 0 - 100 point scale by appropriate multiplication.
Sensitivity analyses
The first sensitivity analysis will involve multiple impu-
tation for missing data, following the approach used in
the analysis of the NHS acupuncture for headache trial
[7]. In brief, results for patients failing to complete data
are imputed using statistical models that are based on
available data and take into account sampling variation.
The second sensitivity analysis will be for publication
bias. Although we do not believe that there will be
many unpublished adequately concealed acupuncture
trials large enough to have an important weight in the
meta-analysis, we will give characteristics of scenarios
that could change the study results. For example, if we
found a statistically significant difference between acu-
puncture and sham, we would estimate the parameters
for the following scenarios of trials which, if added to
the meta-analysis, would change the p value to 0.05: a)
the number of trials with 50 patients per group and no
differences between groups; d) the number of trials with
50 patients per group and an effect size of 0.25 in favor
of control.
The third sensitivity analyses will omit subsets of trials
based on trial quality. We will first omit trials graded as
‘B’ for blinding from the comparison of acupuncture to
sham. We will then repeat all analyses separately omit-
ting trials that score fewer than 5 on the assessment of
acupuncture adequacy.
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Our final sensitivity analysis will be to add the results
of studies for which we did not receive individual
patient level data. We will calculate an estimate of the
difference between groups and the standard error
thereof from published summary data. As we will have
individual patient data from all of the large trials of acu-
puncture, we do not believe that any remaining trials
will have an important weight in the meta-analysis.
Additional analyses
Variation in the effects of acupuncture by indication
To determine whether the effects of acupuncture vary
by indication, we will combine data into a single model
predicting the standardized primary endpoint using
baseline score, trial, indication, treatment and treatment
by indication interaction, and test the hypothesis that all
interaction terms are equal to zero. This analysis will be
conducted separately for acupuncture vs. sham and acu-
puncture vs. no acupuncture control.
Analysis of acupuncture characteristics In these ana-
lyses, we will examine whether characteristics of the
acupuncture treatment affect outcome. We will examine
the following trial level characteristics: number of ses-
sions; frequency of sessions; duration of sessions; point
prescription (fixed needle formula/flexible formula/indi-
vidualized); stimulation (none/manual/electrical/both);
prescription (local points only/distal points only/both
local and distal points); ‘style’ of acupuncture (’Wes-
tern’/traditional Chinese/other); ‘De qi’ needle sensation,
whether felt by practitioner or patient (sought/not
sought); number of needles used; use of adjunctive
therapies such as moxibustion (yes or no); acupuncture-
specific patient practitioner interactions (yes or no);
minimum years of practice as practitioner requirement
to be participating in trial. Patient levels characteristics
to be examined are as follows: sex of acupuncturist; age
of acupuncturist; medical training (MD, other profes-
sional qualification); length of acupuncturists’ training in
hours; years of experience as acupuncturist. Each char-
acteristic will be examined separately using an interac-
tion analysis of the complete data set, with trial entered
as a fixed effect. For example, to determine whether
number of sessions influences the effect of acupuncture
our model would be:
Standardized final score 1Standardized baseline score 2= + . . .
.
Acupuncture 3 Number of





Here ‘acupuncture’ is coded 0 or 1 for control and
treatment groups respectively. A significance test for b4
would then be used to test the hypothesis that the
effects of acupuncture depend on the number of treat-
ment sessions. If indicated, we may include several char-
acteristics of acupuncture in a multivariable analysis
although it is possible that there may be collinearity
(e.g. trials that allowed individualized treatment also
allowed acupuncture specific patient practitioner
interactions).
Analysis of the effects of sham control In this analysis,
we will address the question of whether different types
of sham control have different effects. In the first analy-
sis, we will compare sham to control using the methods
described above for the comparison of acupuncture to
sham. We will report the effect sizes for the three types
of sham - penetrating needle, non-penetrating needle,
non-needle - and compare formally by meta-regression
using two dummy variables - needle (coded 1 for pene-
trating needle and non-penetrating needle and 0 for
non-needle) and penetration (coded 1 for penetrating
needle, 0 otherwise). We will conduct three exploratory
analyses: following the work of Sanchez Aranjo [38], we
will use an additional variable for site of needling coded
1 for any needle penetration in the same dermatome as
the active points and 0 otherwise; we will also add a
variable for depth of insertion of the sham (superficial
or not); for non-penetrating needles, we will determine
whether devices placed at true acupuncture points have
different effects to those placed away from true points.
Indication (shoulder pain, headache, osteoarthritis, mus-
culoskeletal pain) will be entered as a covariate in these
analyses.
Time course of acupuncture effects To estimate the
time course of acupuncture effects, we will use a longi-
tudinal model, that is, we will take into account the
correlation between an individual patient’s scores. We
will use pain score as the dependent variable, baseline
score, time and indication (headache, back or neck
pain, shoulder pain, osteoarthritis), trial and acupunc-
ture as predictors. In this analysis, we will use all time
points in a trial, not just the time point specified as
primary by the study authors. We will compare both
acupuncture to sham and acupuncture to no acupunc-
ture control in this analysis. The analysis will be
repeated separately for each indication. The xtgee com-
mand will be used in Stata. The results will be pre-
sented numerically and also graphed with standardized
mean difference as the y-axis and time since randomi-
zation as the x-axis. This will give a visual representa-
tion of how the benefits of acupuncture, if any, change
over time. It will also allow estimation of effect size at
specific times after randomization. As a secondary ana-
lysis, we will explore whether differences in the time
course of acupuncture effects depends on the duration
of acupuncture treatment. For example, the effects of
acupuncture at six months may differ for a trial in
which treatment is completed within 6 weeks, and in
which treatment effects have 20 weeks to taper off,
than for a trial in which patients are treated for 4 or
5 months. In this secondary analysis, time from last
acupuncture treatment will be added as a covariate.
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Analysis of acupuncture responders Some acupunctur-
ists claim that a subset of patients, who are difficult to
identify in advance, are acupuncture ‘responders’ and
have exceptional improvements after acupuncture ther-
apy. We will test this hypothesis by thinking in terms of
statistical distributions: if a subset of patients has unu-
sual improvements after acupuncture, we would expect
the distribution of change scores to have greater abso-
lute skew in the acupuncture group than in controls.
Accordingly, we will calculate the skew in standardized
change scores for acupuncture and control groups sepa-
rately, compute the difference in the skewness statistic
and estimate a standard error for this difference by
bootstrapping. The difference in skew and standard
error of each trial will then be meta-analyzed. We will
initially compare acupuncture to combined sham and
no acupuncture control groups; subsequent analysis will
compare acupuncture to sham and no acupuncture con-
trol separately. We will also calculate a p value for each
trial separately by permutation methods: we will ran-
domly permute the indicator for group, calculate the dif-
ference in skew, repeat 10,000 times and calculate a p
value for each trial as the proportion of times that the
resulting statistic is equal to or greater in absolute size
than the skewness calculated for the original data.
Analysis of differences between practitioners We will
examine heterogeneity between practitioners, that is,
whether some acupuncturists get better results than
others. In our initial analysis, we will estimate heteroge-
neity for each trial separately by running the principal
analysis - analysis of covariance with baseline score and
randomization strata as covariates - separately for each
practitioner. The resulting coefficients and standard
errors will be combined and heterogeneity statistics cal-
culated [37]. For a meta-analysis of differences between
practitioners, each practitioner’s coefficient will be stan-
dardized by calculating the absolute difference from the
group level estimate of acupuncture effects. For exam-
ple, if in a trial, the mean difference between groups cal-
culated in the primary analysis was 0.5 standard
deviations, and the difference for one practitioner was
0.4 standard deviations, the value 0.1 would be entered
into the meta-analysis.
Analysis of predictors of acupuncture effect In these
analyses, we will examine effect modifiers, defined as
characteristics of a patient, known before treatment,
that influence the degree of benefit experienced by that
patient. An example is Her-2/neu overexpression modi-
fication of Herceptin effect in a patient with advanced
breast cancer: the likelihood that a patient’s tumor will
respond to Herceptin depends on whether or not the
tumor overexpresses Her-2/neu. Effect modifiers will be
examined by an interaction analysis of the complete
data set, with trial entered as a fixed effect. For example,
to determine whether age influences the effect of acu-
puncture, our model would be: Standardized final score
= b1. Standardized baseline score + b2. Acupuncture +
b3. Age + b4. Age × Acupuncture. A significance test for
b4 would then be used to test the hypothesis that the
effects of acupuncture are different in older compared
to younger patients. We will test the effects of the fol-
lowing variables: age, sex, disease duration, baseline
severity, baseline psychological distress. We may also
examine indication-specific effect modifiers, for example,
pain radiating to the legs in back pain trials: this will
depend on the availability of these data in the meta-ana-
lyzed trials.
Implementation of the meta-analysis A series of steps
will be taken before each meta-analysis is conducted.
1. Initial data collection. A list of trials potentially
eligible for the meta-analysis will be created. For
example, a two-arm trial of acupuncture versus
sham for the treatment of low back pain will be
included for a meta-analysis of acupuncture versus
sham for musculoskeletal pain, but not in a meta-
analysis of acupuncture versus usual care, or one
focusing on neck pain. If there are fewer than three
eligible trials, meta-analysis will not be attempted
and steps 2 - 5 will be omitted.
2. Consultation. The statistical center will prepare
the following and make available to each
collaborator:
a. A full copy of the main publication for each
trial
b. Annotated statistical code that will describe,
step-by-step, the statistical analyses to be under-
taken. This document will be written broadly so
that it will apply to analyses of all pain types,
endpoints, time points and so on. In order to
illustrate how the code will work, collaborators
will also receive a print-out of the results from
running the code on a data set where the indica-
tor for treatment has been randomly permuted.
3. Comment period. Each collaborator will then have
a four week period in which to:
a. Agree to the inclusion of all trials in the meta-
analysis
b. State that one or more trials should not be
included, giving a reason for each
c. Ask for more time.
4. Collation of data. The results of the collaborator
comments will be combined.
a. If no collaborator recommends exclusion of
any trial, we will move to step 5
b. If there is consensus that one or more trials
should be excluded, the reasons will be docu-
mented and we will move to step 5
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c. If there is disagreement over the inclusion of
one or more trials, a description of the disagree-
ment - the trials concerned, and the reasons why
some collaborators are suggesting exclusion -
will be distributed to all collaborators
d. A vote on each trial will then be taken
5. Decision on the trials to be included in the meta-
analysis.
a. A final list of trials will be generated.
b. If there are only three trials, the statistical
code for the meta-analysis will be run up to the
point where meta-analytic weights are calculated.
If the fixed effect weight for a single trial is 75%
or greater, the meta-analysis will be halted and
no further action will be taken; otherwise, the
meta-analysis will proceed as in point 6.
c. If a meta-analysis includes more than three
trials and one trial has a weight of 75% or
greater, an adjustment will be made to weighting
factors. The standard error of the largest trial
will be increased by 25% and the weights recal-
culated. If the weight of the largest trial is less
than 75%, we will proceed to step 6. Otherwise,
the standard error of the largest trial will be
increased by 33% and the weights recalculated. If
the weight of the largest trial is less than 75%,
we will proceed to step 6. Otherwise, meta-analy-
sis will be halted.
6. Final implementation of the meta-analysis.
a. The remaining statistical code will be run and
results will be written up by the statistics team
and distributed to all collaborators.
Discussion
We believe that the findings of the Acupuncture Trial-
ists’ Collaboration will have important implications for
both clinical practice and research. Individual patient
data meta-analysis of high quality trials will provide the
most reliable basis for treatment decisions about acu-
puncture. Analyses as to the impact of different sham
techniques, styles of acupuncture or frequency and
duration of treatment sessions will no doubt guide
future clinical trials of acupuncture.
Above all, however, we hope that our approach can
serve as a model for future studies in acupuncture and
other complementary therapies. In the Acupuncture Tri-
alists’ Collaboration, a group of trialists, statisticians and
other researchers has come together to share raw data
and develop, in partnership, a set of research questions
and associated analytic strategies. We strongly believe
that it is only by breaking down the oppositional culture
of competing trialists, and sharing data in a robust
scientific collaboration, that we can best translate clini-
cal trial findings into patient benefit.
Additional material
Additional file 1: Outcome Measure Preferences. This document is to
guide the selection of endpoints to be included in the meta analyses.
Endpoints are classified by domain (e.g. WOMAC pain is in the “pain
intensity” domain; days of headache is in the “pain frequency” domain).
This document specifies which endpoint should be chosen if a trial has
data on more than one endpoint per domain. In general, we have given
preference to measures that are specific to pain types, then to the most
widely used measures.
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